Nightingale Health

Before it’s time to head to the holidays, we wanted to bring some festive cheer to those in need. ❤️ Joulupuu is a Finnish charity dedicated to collecting gifts for children and every donated gift will be distributed to children who might not experience the joy of receiving presents without the Joulupuu campaign.   At Nightingale Health, we had the pleasure of participating in the Joulupuu campaign as our Flock members could bring gifts to the office.🎄🎁 Last week, we embraced the true spirit of the season as we wrapped presents and delivered them to bring joy to children in need. The campaign is truly a meaningful way to give back.   Let’s carry this spirit of giving forward and make the season just as magical for as many children as possible. ✨   Ps. If you would like to join us, learn more from: https://lnkd.in/dPV4DYmx

New in heart disease and type 1 diabetes research 💡 Exciting advancements from the FinnDiane Study Group in understanding the risk for heart disease among people with type 1 diabetes. A recent study from the Finnish Diabetic Nephropathy Study explored urine metabolites analyzed by Nightingale Health to uncover insights into heart disease risk. By analyzing data on 2501 participants followed for 10 years after urine sampling, the researchers identified novel metabolites associated with elevated risk for heart disease. These metabolites include lower levels of 3-hydroxyisobutyrate (linked to younger age and better kidney function) and higher levels of xanthosine (related to oxidative stress). These findings provide valuable insights into the role of urinary metabolites as markers of future risk, not only for kidney disease but many other common cardiometabolic diseases. The analyses showed that these metabolites may significantly improve the prediction of future heart disease onset, particularly for short-term risk assessment.    Access the publication: Antikainen et al. Urinary metabolomics provide insights into coronary artery disease in individuals with type 1 diabetes. Cardiovascular Diabetology 2024 https://lnkd.in/eZ58rW4Q Learn more about our CoreMetabolomics Urine platform for research: https://lnkd.in/d_G3WJSN 

We are excited to welcome our new Office IT Manager, Kimmo Salmelainen, as the newest member of our People team. 🥳   Kimmo has worked as a consultant before at our company, and after a successful collaboration in the past, we’re delighted to have him join our team:   💬 "Having previously worked with Nightingale Health, I immediately felt welcome and appreciated the great work ethic and the amazing team. Even back then, I loved the work I was doing here and felt I could have achieved even more with additional time. I was lucky enough to have my onboarding day around the time of the pre-Christmas party and got to join the event. It was a great way to meet my new colleagues and reconnect with those who remembered me from before, all while singing karaoke and enjoying our own band performing."   Kimmo believes his role gives him the opportunity to share his skills and experience:   💬 "I like that my colleagues are eager to share their ideas and needs. This makes my role not only dynamic and exciting but also allows me to feel truly valued. While I'm still learning about our company, I am confident that my contributions in automation, accessibility, ease-of-use, and premium support, with a strong focus on security, will have a lasting impact."   Welcome to the team Kimmo, we are happy to have you onboard! 💜

The season of celebration and cheer is here! A couple weeks ago we had the grand opening of Helsinki's most glamorous Nightclub Nightingale. 🤩   As we stepped into the glow of the party lights, we had the chance to enjoy the DJ's electrifying beats, while enjoying delicious pub food and a mind-stretching pub quiz about our company.   As the night moved on, we experienced the eagerly awaited highlight of the evening – the performance by The Nightingales band, which set the perfect tone for the night! 🎶🪩 With a spectacular show, our house band truly ignited the party, while our gifted team members rocked the stage, wowing the nightclub audience with their impressive performances. Following the awesome gig, we were treated to our team's incredible talent during the nightclub's karaoke session. 🎤   It was a fantastic way to share the spirit of the season with the amazing people who make our workplace shine. 🌟   We can’t wait to celebrate again with the most vibrant, talented team around! 💜✨

Nightingale Health's peer-reviewed study has been published in Nature Communications, showcasing the accuracy and performance of Nightingale Health’s blood biomarker-based risk prediction models. The world’s largest population study in the field includes data from more than 700,000 participants in three national biobanks from Finland, Estonia and the United Kingdom.

Are you attending the UK Biobank Scientific Conference in London on December 10? Nightingale Health has completed the analysis of all 500,000 UK Biobank samples creating the world’s largest blood biomarker database for chronic disease research and prevention. Our Founder & Scientific Advisor, Peter Würtz, and Head of Global Medical Research Business, Helena Sundberg, will be at the event and would love to connect with you and tell more! Book a meeting to discuss more: research@nightingalehealth.com

Today, we had the the opening ceremony of our Singapore laboratory. The laboratory is now ready to serve healthcare and medical research customers in the Southeast Asia region. “With the laboratory set up completed, we can now focus on our sales activities at full speed together with our partner Innoquest Diagnostics and we are expecting the first healthcare samples to the lab in the first quarter of 2025” Satu Saksman, COO and Co-founder, Nightingale Health. Thank you everyone who joined the event to celebrate with us! 💜 Read more about the opening of our Singapore laboratory: https://lnkd.in/eEyTkdeS

  Exciting news from Singapore! Nightingale Health announces opening of its Singapore laboratory 🎊 Nightingale Health announced earlier this month that it has the regulatory readiness to start providing its blood analysis service in Singapore. In parallel with the regulatory processes, Nightingale Health has been setting up the laboratory and data processing readiness, and that work has now successfully been accomplished. After opening the laboratory, the main focus of the project will be shifted towards commercial activities. “With the laboratory set up completed, we can now focus on our sales activities at full speed together with our partner Innoquest Diagnostics and we are expecting the first healthcare samples to the lab in the first quarter of 2025” says Satu Saksman, Nightingale Health's COO and Co-founder, who leads the operations in Singapore. “We’d like to welcome our partners, customers and other stakeholders to celebrate this achievement, which is the result of hard work from multiple teams both within Nightingale Health and Innoquest Diagnostics.” Saksman continues. Read more: https://lnkd.in/eEyTkdeS

Welcome to our webinar “Prediction of type 2 diabetes complications using metabolomic profiles” on 4 December at 11 a.m. EST! Join us for a session on the potential of metabolomic data from the UK Biobank cohort, focusing specifically on individuals with type 2 diabetes. In this webinar, our Data Scientist, Kirsten Schut, will highlight how metabolomic profiles not only predict diabetes onset but also reveal insights into the progression of diabetes-related complications and mortality. Learn more and sign up: https://lnkd.in/ezyBC8v6

Greetings from UK! 🇬🇧 We are delighted to introduce our new team member Dr. Charles Alessi, who has taken on the role of Chief Medical Officer of Nightingale Health UK. 🥳   Charles believes that his work is at the heart of our mission to build sustainable healthcare and reduce health inequalities:   💬 "At Nightingale Health, I see myself as being part of the movement to get our incredible technology deployed in the mainstream of healthcare systems everywhere. As a physician, I have always thought that we were missing a trick merely treating disease. Would it not make more sense to also prevent it? Our technology makes this possible, and I wanted to be at the heart of this change in health and care. There was nowhere better to be."   For Charles, the friendships formed are the standout highlight of being part of the company:   💬 "I felt part of the team from day one and my family now extends to Finland. What I have enjoyed most in my daily work is the close collaboration with key colleagues. After a few weeks, I already feel I have known them forever. Working in the UK obviously lacks the immediacy of face-to-face contact with colleagues based in other countries, but we all do our best to make up for this and seem to be successful at doing so."   A very warm welcome, Charles! We’re excited and honoured to have you on board. 💜